Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic mesenchymal stem cells (University of Illinois at Chicago)
- Development stage
- Unknown
- Lead developer
- University of Illinois Chicago
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
This investigational cell-based therapy, developed by the University of Illinois at Chicago, consists of allogeneic bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of neurotrophic keratitis and non-healing corneal epithelial defects. Administered via subconjunctival injection, the therapy aims to facilitate corneal repair by utilizing the regenerative, trophic, and immunomodulatory properties of MSCs. The cells are produced under Good Manufacturing Practice (GMP) conditions at the University of Illinois Hospital Clinical Stem Cell Laboratory. A Phase 1 dose-escalation study (NCT04626583) is currently evaluating the safety and maximal tolerated dose of this biologic modality in patients with persistent corneal wounds, supported by the Department of Defense Vision Research Program.
- Other names
- Allogeneic MSCAllogeneic bone marrow-derived mesenchymal stem cellsAllogeneic Mesenchymal Stromal Cells
Beyond the preview
Go deeper on Allogeneic mesenchymal stem cells (University of Illinois at Chicago).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic mesenchymal stem cells (University of Illinois at Chicago).